Holen Sie sich die Stockscreener-App
136.30
2.11%
2.82
Handel nachbörslich:
136.30
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$133.48
Offen:
$133.38
24-Stunden-Volumen:
6.21M
Relative Volume:
0.97
Marktkapitalisierung:
$169.18B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
20.10
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
+5.79%
1M Leistung:
-2.73%
6M Leistung:
+10.45%
1J Leistung:
+39.25%
1-Tages-Spanne:
$133.19
$136.75
1-Wochen-Bereich:
$127.96
$136.75
52-Wochen-Spanne:
$95.30
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
136.30 | 165.68B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
987.05 | 881.82B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.62 | 542.95B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
205.03 | 364.56B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.92 | 281.08B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
148.36 | 277.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
7 months after last layoffs, Bay Area biotech giant does another round - SFGATE
California Justices Scrutinize Gilead Patients’ Liability Theory - Bloomberg Law News
Bay Area biotech takes another hit as Gilead announces major job cuts - SFGATE
California's highest court leans toward Gilead in considering drugmakers' 'duty to innovate' - Reuters
Airbnb, McKesson, Gilead and more set to report earnings Thursday - Investing.com
Gilead Sciences Q1 2026 Earnings Preview: Steady growth ahead? (GILD:NASDAQ) - Seeking Alpha
Can We End the HIV Epidemic Once and for All? This Researcher Thinks So. - Men's Health
Gilead to lay off dozens in Rockville after closing Arcellx acquisition - The Business Journals
Swedbank AB Buys 43,205 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 129,186 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Sprucegrove Investment Management Ltd. - MarketBeat
Principal Financial Group Inc. Buys 379,592 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Equitable Trust Co. Has $6.07 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow - The Globe and Mail
Gilead to cut more than 100 Bay Area jobs - KRON4
Gilead to lay off nearly 200 workers after Arcellx acquisition closes - The Business Journals
Bay Area biotech giant Gilead to lay off 108 workers in Redwood City - San Francisco Chronicle
Gilead Fights ‘Limitless’ Liability at California High Court - Bloomberg Law News
Use of Gilead's HIV prevention shot rises, but US insurance gaps remain - Reuters
Morse Asset Management Inc Invests $1.22 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by QRG Capital Management Inc. - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by M&T Bank Corp - MarketBeat
Alliance Wealth Advisors LLC UT Cuts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Earnings Notes - Trefis
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir - European AIDS Treatment Group
Gilead Shareholders Back Board, Pay Plans at 2026 Meeting - TipRanks
Gilead Sciences Completes Acquisition of Arcellx to Strengthen Oncology Portfolio - Oncodaily
Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Varma Mutual Pension Insurance Co Cuts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to Acquire Tubulis to Advance Targeted Cancer Therapies - The Healthcare Technology Report.
Gilead Sciences, Inc. $GILD Shares Bought by Triasima Portfolio Management inc. - MarketBeat
Intact Investment Management Inc. Has $10.36 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Can You Sue A Drug Company For Not Inventing Faster? - Yahoo Finance UK
Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)? - simplywall.st
Benjamin Edwards Inc. Has $16.60 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
FDA Priority Review For New HIV Combo Might Change The Case For Investing In Gilead Sciences (GILD) - simplywall.st
Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
PFA Pension Forsikringsaktieselskab Purchases Shares of 826,930 Gilead Sciences, Inc. $GILD - MarketBeat
Robertson Stephens Wealth Management LLC Has $6.27 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sigma Planning Corp - MarketBeat
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story - Yahoo Finance
Assessing Gilead Sciences (GILD) Valuation As Long Term Returns Contrast With Recent Share Performance - Yahoo Finance
Gilead Sciences Stock: Three Acquisitions, Four Launches, and a 20% Discount to Wall Street’s Target - TIKR.com
The Freelux Project Announces “The Butch Queen’s Brunch & Conversations Tour” Powered by Gilead Sciences - GLAAD
Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System - MarketBeat
Oppenheimer & Co. Inc. Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Jennison Associates LLC Buys 741,044 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
US Bancorp DE Has $105.44 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences - The AI Journal
Danske Bank A S Sells 45,529 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Fifth Third Bancorp Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):